Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center reviews
the limited data that help clarify the probability of benefit from
new immunotherapy agents among patients with advanced NSCLC and an
identified driver mutation.
About the Podcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.